Novartis　

2006/12/14 Nestle

Nestle to Acquire Novartis Medical Nutrition, Moving Toward Nutrition, Health and Wellness

As a part of its continuing efforts to reinforce the Group's leading position in nutrition, Nestle has agreed to acquire the entire medical nutrition business of Novartis for a total amount of USD 2.5 billion. The move propels Nestle into a strong number two position in the fast growing and profitable healthcare nutrition segment, where so far Nestle played only a minor role. Through this acquisition Nestle also strengthens its existing R&D capability, helping to accelerate the growth of the nutrition business.

---

日本経済新聞　2006/12/15

医療用食品でネスレは世界5位でノバルティスは2位。今回の買収でネスレのシェアは25%となり、最大手でシェア30%の米アボット･ラボラトリーズに次ぐ2位に浮上する。

April 07, 2008 Novartis

Novartis to further strengthen its healthcare portfolio by acquiring 25% stake in Alcon from Nestlé with right to take over majority ownership of the world leader in eye care

• Definitive agreement with Nestlé S.A. provides Novartis the right to acquire 77% majority ownership of Alcon in two steps

• Novartis to first acquire 25% stake from Nestlé for USD 143.18 per share for approximately USD 11 billion, closing expected in second half of 2008

• In optional second step, Novartis has exclusive right to acquire Nestlé's remaining 52% stake for a fixed price of USD 181 per share, totaling about USD 28 billion; Nestlé has right to require Novartis to buy this stake

• Alcon the world leader in eye care with its pharmaceutical, surgical and consumer eye care products, and a highly-rated development pipeline

• Eye care market growing dynamically, driven by increase in age-related eye diseases, global expansion and novel therapies

• Strong strategic fit with complementary Novartis contact lens and ophtha pharmaceutical businesses; synergies expected to be realized in due time

アルコンは1945年に米テキサス州で薬局として創業し、点眼薬やコンタクトレンズケア商品など眼科分野の最大手メーカー。78年にネスレが買収し、77%の株式を保有する。

Nov 3, 2009 Reuters

Novartis invests $1 bln in China R&D plant

* Emphasises importance of emerging markets
* Invests further $250 mln in second plant

Swiss drugmaker Novartis AG is investing $1 billion to build the largest pharmaceutical research plant in China, emphasising the importance of developing markets for future growth.

Novartis and other drugmakers are keen to tap into markets such as China as they face slowing growth and loss of exclusivity on key products, including the Swiss group's top-selling blood pressure medicine Diovan. Novartis said it was also investing $250 million in a second research and development and manufacturing facility in Changshu 江蘇省常熟市.

The Switzerland-based drug maker launched an integrated biomedical R&D center in Shanghai's Zhangjiang Hi-Tech Park 張江ハイテクパーク　two years ago and has already invested US$100 million in the center. The primary research at the center covers cancer as well as innovative chemistry and biomarket.

The company aims to deepen cooperation with Shanghai and build the R&D center into China's largest integrated bio-pharmaceutical R&D center by next year, said the English-language news paper.

Novartis has teamed up with the Institute of Biomedical Science of Fudan University 復旦大学 for cancer research in 2008.

Novatis' China sales jumped 29% from a year ago to RMB 3.3 billion last year, accounting for nearly 8% of its global sales.